Gut
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
Taotao Sheng, Raghav Sundar, Supriya Srivastava, Xuewen Ong, Su Ting Tay, Haoran Ma, Tomoyuki Uchihara, Benedict Shi Xiang Lian, Takeshi Hagihara, Mei Suen Kong, Chang Xu, Shamaine Wei Ting Ho, Kie Kyon Huang, Angie Lay Keng Tan, Michelle Shu Wen Ng
Published: 202510.1136/gutjnl-2024-334667
Abstract
BACKGROUND: Human epidermal growth factor receptor 2 (HER2; ERBB2) is overexpressed or amplified in 15-20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ERBB2 expression is often variable. Although HER2 therapeutic targeting improv…
Preview only. Read the full abstract at the source